Consequently, regulatory authorities and the medical community have shown a growing interest in TRK-targeted therapies, illustrated by the tumor-agnostic approvals received by entrectinib and larotrectinib worldwide and the increasing number of TRK inhibitors currently in development. This evidence concerns the gene TPM3 and neoplasm.